335 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 29332 | Laura Polastro | Ovary | Merck | MK-3475-B96/KEYNOTE-B96/ENGOT-ov65 | Trial closed for recruitment | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTEB96/ ENGOT-ov65) | laura.polastro@hubruxelles.be | 3 | 3 | ||
| 28956 | Spyridon Sideris | Kidney | Merck | MK-6482 PN011 | Trial closed for recruitment | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy |
spyridon.sideris@hubruxelles.be | 3 | 3 | ||
| 22736 | Roll-over of other trials with pembrolizumab | Andrea Gombos | Multiple | MSD (Merck Sharp & Dohme) | MK3475-587 | Trial closed for recruitment | A Multicenter, Open Label, Phase III Extension Trial to study the Long-term Safety and Efficacy in Participants with Advanced Tumors who are currently on Treatment or in Follow-up in a Pembrolizumab Trial (MK3475-587) | accueil.oncologie@hubruxelles.be | 3 | 3 | |
| 22828 | BRAF V600 mutation | Joseph Kerger | Skin | Roche | ML29741 | Trial closed | A Single Arm, Open Label, Phase II, Multicenter Study To Assess The Detection Of The Braf V600 Mutation On cfDNA From Plasma In Patients With Advanced Melanoma | joseph.kerger@hubruxelles.be | 2 | 2 | |
| 22826 | first line, RECIST 1.1 | Alain Hendlisz | Colon | Roche | MO29112 | Trial closed | A multi-centre randomized clinical trial of Biomarker-Driven maintenance treatment for first-line metastatic colorectal cancer (MODUL) | alain.hendlisz@hubruxelles.be | 2 | 2 | |
| 22747 | ER+/HER2-. Metastatic. Pre-menopausal | Andrea Gombos | Breast | Novartis | MONALEESA-7 | Trial closed | A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer | accueil.oncologie@hubruxelles.be | 3 | 3 | |
| 22753 | HR+/HER2- | Ahmad Hussein Awada | Breast | Lilly | MONARCH3 I3Y-MC-JPBM | Trial closed | A randomized, double-blind, placebo-controlled, phase 3 study of nonsteroidal aromatase inhibitors (anastrozole or letrozole) plus LY2835219, a CDK4/6 inhibitor, or placebo in postmenopausal women with hormone receptor-positive, HER2-negative locoregionally recurrent or metastatic breast cancer with no prior systemic therapy in this disease setting | ahmad.awada@hubruxelles.be | 3 | 3 | |
| 29693 | Francesco Sclafani | Multiple | Seagen | Mountaineer-03 | Trial open for recruitment | An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer(SGNTUC-029 - Mountaineer-03) | francesco.sclafani@hubruxelles.be | 3 | 3 | ||
| 29751 | Mariana Brandao | Lung | Merck | MS201924-0022 | Trial open for recruitment | An open-label, multicenter, phase 1b/2a study to evaluate efficacy, safety, tolerability, and pharmacokinetics of the ATR inhibitor M1774 in combination wit cemiplimab in participants with non-squamous non-small cell lung cancer that has progressed on prior anti-PD-(L)1 and platinum-based therapies | mariana.brandao@hubruxelles.be | 1b | 1 | ||
| 22724 | ER+/HER2-. Adjuvant. Pre or post menopausal | Andrea Gombos | Breast | Novartis | NATALEE | Trial closed for recruitment | A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAl with Ribociclib [LEE011]: NATALEE) (CLEE011O12301C (TRIO033)) |
accueil.oncologie@hubruxelles.be | 3 | 3 | |
| 28570 | NTRK | Philippe Aftimos | Multiple | Bayer | NAVIGATE | Trial closed | A Phase 2 Basket Study of the Oral TRK Inhibitor larotrectinib in Subjects with NTRK Fusion-Positive Tumors | philippe.aftimos@hubruxelles.be | 2 | 2 | |
| 22749 | Subject is able to receive radiotherapy and surgery | sarcome | Nanobiotix | NBTXR3-301 Nanobiotix | Trial closed | A multicentre randomized, open-label Phase II/III study, to compare the efficacy of NBTXR3, implanted as intratumor injection and activated by radiotherapy, versus radiotherapy alone in patients with locally advanced soft tissue sarcoma of the extremity and trunk wall | 2/3 | 2 | |||
| 22630 | ER+/HER2-. Neoadjuvant. Palbociclib | Michail Ignatiadis | Breast | Institut Jules Bordet | NEORHEA | Trial closed | Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined with Endocrine Therapy in Estrogen Receptor Positive/ HER2 Negative Breast CAncer | michail.ignatiadis@hubruxelles.be | 2 | 2 | |
| 22728 | RECIST v1.1 | Christiane Jungels | Soft tissue | SpringWorks Therapeutics | NIR-DT-301 | Trial closed | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors (DTs)/Aggressive Fibromatosis (AF) | christiane.jungels@hubruxelles.be | 3 | 3 |